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Autocatalytic changes in the conformation and aggregation
state of prion protein appear to be fundamental to
transmissible spongiform encephalopathies or prion
diseases. Here we review the considerable progress that
has been made in describing the normal properties of
prion protein and the changes that occur during these
devastating neurodegenerative diseases.
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Introduction
Transmissible spongiform encephalopathies (TSE or prion
diseases) are fatal neurodegenerative diseases of humans
and animals. TSE diseases can be subdivided into three
groups on the basis of the etiology: infectious, genetic and
sporadic. About 85% of Creutzfeldt–Jakob disease (CJD)
cases are sporadic, that is, not due to an obvious infection
or prion protein (PrP) gene mutation. Familial CJD
(fCJD), Gerstmann–Sträussler–Scheincker disease (GSS),
and fatal familial insomnia (FFI) are inherited diseases in
humans that are associated with specific mutations of the
PrP gene. Animal TSEs, as well as Kuru, iatrogenic CJD
(iCJD), and new variant CJD (nvCJD) in humans, are
caused by the acquisition of an infectious agent. Scrapie in
sheep and goats, and chronic wasting disease (CWD) in
elk and deer appear to spread horizontally and/or vertically
amongst animals naturally. Other TSEs of infectious origin
are caused by unfortunate human-mediated events, such
as contamination of food sources, medical products or sur-
gical instruments. Whatever the primary disease etiology,
one common hallmark is the accumulation of abnormally
protease-resistant forms of host-derived PrP in the central
nervous system and, to a lesser extent, in lymphoreticular
tissues. These TSE-associated forms of PrP have been
termed PrPSc, PrPCJD, PrPBSE, and so on, according to the
particular TSE involved or, more operationally, PrP-res for
protease-resistant PrP. Diversity in the structures and
properties of various abnormal PrP molecules, however,
has made the precise definitions and use of these terms
problematic (see below). Nonetheless, with that caveat, we
will use the generic term PrP-res, unless referring specifi-
cally to the abnormal PrP forms associated with a particular
TSE disease. 
Much evidence suggests that abnormal forms of PrP of
some sort are critical in the transmission and pathogenesis
of TSE diseases (reviewed in [1,2]). Indeed, it has been
proposed that PrP-res is itself the infectious TSE agent or
prion [3]. However, although considerable progress has
been made in understanding the structures and folding
options of various PrP molecules, no noninfectious form of
PrP has been converted to an infectious agent in a system
that explicitly prohibits nucleic acid, and hence viral,
replication. Thus, the precise nature of the agent is
unclear. Here we review recent studies of relevance to the
formation of TSE-associated forms of PrP.
TSE-associated changes in PrP
Normally, PrP is a protease-sensitive sialoglycoprotein
which binds copper and is anchored to plasma membrane
via glycosyl-phosphatidylinositol (GPI; reviewed in [1–3]).
Here we will use the term PrPC to refer to PrP in its
normal structure and conformation and the term PrP-sen
to refer generically to protease-sensitive forms of PrP,
whether normal (i.e., PrPC) or not (e.g., various recombi-
nant forms). PrPC and PrP-res are encoded by the same
host gene and appear not to differ consistently in covalent
structure. However, the two isoforms can be readily distin-
guished in other ways (reviewed in [1–3]). The biosynthe-
sis of PrP-res is much slower than that of PrPC as PrP-res
is made from mature PrPC after it reaches the cell surface.
Once it is formed, PrP-res is much more resistant to prote-
olysis than is PrPC and has a longer metabolic half-life.
Whereas proteinase K (PK) fully digests PrPC, it usually
removes only ~67 of the ~210 total residues from the
N terminus of most PrP-res (PrPSc and PrPCJD) molecules.
In addition, PrPC is soluble in mild detergents, whereas
PrP-res is much less soluble and tends to assemble into
amorphous aggregates or amyloid fibril-like structures
(scrapie-associated fibrils or prion rods).
Circular dichroism (CD) studies showed that PrPC has
high α-helical content but little β-sheet content [4]. More
recently, the determination of high-resolution nuclear
magnetic resonance (NMR) structures of various recombi-
nant PrP-sen molecules has confirmed the high α-helical
and low β-sheet content of PrP-sen [5–9]. The high-reso-
lution three-dimensional structure of a C-terminal domain
of mouse PrP-sen (residues 121–231) was the first to be
determined [5]. Subsequent studies with full-length
recombinant PrP-sen molecules (residues ~23–231) or
PrP-sen fragments corresponding to the usual protease-
resistant core of PrP-res (residues ~90–231) have revealed
that residues lying outside of the domain encompassing
residues 121–23 are so flexible as to have little discernible
structure by NMR [6,8]. 
In contrast to PrPC, infrared, CD and X-ray diffraction
analyses have shown PrPSc to predominantly comprise
β-sheet structure with lower α-helical content [4,10–13].
Therefore, the transition of α helix and/or disordered sec-
ondary structures to β sheet is thought to be key to the
conversion of PrPC to PrP-res.
Diversity in abnormal TSE-associated PrP structures
Although the terms PrP-res, PrPSc, and so on, are often
used as if they represent a single conformational state or
entity, it is increasingly apparent that this is an over-sim-
plification. For instance, TSE-associated PrP molecules
can vary in resistance to proteolysis [11,13–16], insolubil-
ity in detergents [14,17], secondary structure (Figure 1)
[13], glycoform ratios [18–22], exposure of epitopes by
denaturants [23], multispectral ultraviolet fluorescence
[24] and ultrastructure [25–27]. The fact that PrPSc can be
purified as a mixture of both partially PK-resistant and
fully PK-sensitive molecules [28] is another source of
complexity. Although there is evidence that the PK-sensi-
tive molecules are not required for infectivity and auto-
catalytic activity (see below) [29], it remains possible that
they are important in neuropathogenesis. Finally, as noted
below, manipulations with various recombinant and
mutant forms of PrP have generated numerous forms of
PrP which appear to share some, but not all, of the proper-
ties of bona fide TSE-associated PrP isolated from infected
tissues. A current challenge is to understand which abnor-
mal states of PrP are relevant to various aspects of TSE
transmission and/or pathogenesis. The requirements may
be different for infectious versus neurotoxic forms of PrP.
With these uncertainties in mind, Weissmann [30] has
proposed the use of the term PrP* to denote the putative
infectious form of PrP, whatever it may be.
Potential mechanisms of PrP-res formation
Among the various mechanisms and permutations of
mechanisms that have been proposed to account for
PrP-res formation, two that are most commonly consid-
ered are the heterodimer or template-assistance-type
model [3,31,32] and the nucleation (seed)-dependent
polymerization model [31,33–35] (Figure 2). In its sim-
plest form, the heterodimer model posits that PrP-res
exists in a stable monomeric state that can bind PrPC,
forming a heterodimer, and catalyzes a conformational
change in PrPC to form a homodimer of PrP-res. The
PrP-res homodimer then splits apart to give two PrP-res
monomers. Fundamental elements in this model are that
PrP-res is more stable thermodynamically than PrPC, and
that conversion of PrPC to PrP-res is rare unless catalyzed
by a pre-existing PrP-res template. 
The most fundamental aspect of the nucleated polymer-
ization model is that oligomerization/polymerization of PrP
is necessary to stabilize PrP-res to allow its accumulation to
biologically relevant levels. The initial formation of nuclei
or seeds of PrP-res is rare because of the weakness of
monovalent interactions between PrPC molecules and/or
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Figure 1
Strain-dependent differences in β-sheet conformations of PrP-res with
or without PK treatment. Second-derivative Fourier transform infrared
spectra of PrP-res isolated from hamsters with either the 263K, hyper
(HY) or drowsy (DY) TSE strains. Although the PrP-res in these
samples are derived from the same hamster PrPC sequence, major
differences are observed between the DY strains and the other two in
the β-sheet region of the spectrum (~1616–1640 cm–1). The data are
consistent with the concept that different PrP-res conformations may
account for the existence and individual properties of different TSE
strains. (The figure was adapted from [13] with permission). 
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the rarity of polymerizable conformers. However, once
formed, oligomeric or polymeric seeds are stabilized by
multivalent interactions [34]. Recruitment of new PrP mol-
ecules would also be favored by multivalent interactions at
seeding surfaces. For instance, in the imaginary schematic
nucleated polymerization models in Figure 2, each newly
recruited molecule contacts three PrP-res molecules in the
seed polymer. With this particular topology, the minimum
nucleus in which each monomeric unit contacts three
others would be a 4-mer (not shown); 2-mers and 3-mers
might be considerably less stable as each monomer would
contact only one or two other PrP molecules.
Clearly, some cross-over occurs between the two types of
models in their various renditions. Autocatalysis of the
conformational change in PrPC by PrP-res can be an
important element of both the template-assisted (e.g.
hererodimer) and nucleated polymerization models
(Figure 2). However, the nucleated polymerization model
could also include a scenario in which PrPC rapidly inter-
changes between the high α-helix and high β-sheet con-
formers, with the latter being poorly populated until it is
stabilized by binding to a pre-existing polymeric seed of
PrP-res (non-catalytic model). In both types of models,
there may be a metastable PrPC folding intermediate that
most favorably interacts with PrP-res in the conversion
reaction. Such an intermediate might resemble those gen-
erated from recombinant PrP-sen under acidic conditions
[36–39] similar to those of endosomes or lysosomes in
intact cells. 
From a biological point of view, a critical question is what
physical state(s) of PrP-res is (are) active in TSE disease
processes in vivo? The nucleated polymerization model
predicts that active PrP-res seeds could range in size from
the minimum stable nucleus (in theory as small as a trimer)
to huge polymers. Consistent with this prediction is the fre-
quent observation that autocatalytic activity (see below)
and infectivity are associated with a wide size range of PrP-
res aggregates, but not monomers [28,29,40,41]. In contrast,
the template-assistance-type models propose discrete
monomers, or perhaps small oligomers, as the active auto-
catalytic unit. Aggregation of PrP-res would then be an
epiphenomenon, albeit one that might serve to further sta-
bilize PrP-res. In a theoretical consideration of the kinetic
consequences and likelihoods of the two models, Eigen
[42] concluded that a strict non-cooperative heterodimer
model is highly unlikely. However, if a small oligomer
(e.g., trimer or tetramer) served as a template in a highly
cooperative autocatalytic reaction, then the model becomes
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Figure 2
Possible models for the formation of PrP-res
from PrPC. In the heterodimer and
autocatalytic nucleated polymerization models,
the conformational conversion of PrPC to PrP-
res is presumed to be extremely rare unless
catalyzed by contact with monomeric or
polymeric PrP-res, respectively. In the non-
catalytic nucleated polymerization model, the
conformational interchange is relatively rapid,
but the PrP-res conformer is poorly populated
unless stabilized by binding to a preformed,
stable PrP-res polymer. Newly formed PrP-res
is shown in a lighter shade of red than the
original. See text for details.
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more plausible. In any case, Eigen suggests that aggrega-
tion of PrP-res is likely to be an important ‘prerequisite of
infection’. Mathematical modeling of the nucleated poly-
merization mechanism by Masel et al. [43] revealed that
systems of short polymers would grow the fastest.
The spontaneous formation of the template or seed of
PrP-res may explain the initial event in inherited and spo-
radic human TSEs that are not of infectious origin, that is,
the formation of the initial template/seed may be a rare
stochastic event. This would account for the relatively late
onset of inherited human TSEs and the fact that not all
people harboring germline mutations develop the disease
within their life span. On the other hand, the transmission
of a TSE agent might be explained by the acquisition of
the template/seed.
PrPSc-induced conversion of PrPC to PrP-res
The above mechanistic models as well as experimental
studies using PrP transgenic mice, PrP-deficient mice
and scrapie-infected cell cultures have strongly implied
that interactions between PrP-sen and PrP-res are
required for the formation of PrP-res and TSE pathogen-
esis (reviewed in [44]). Direct evidence for this concept
was provided by cell-free studies, demonstrating that
PrPSc induces 35S-labeled PrP-sen to convert to a
PK-resistant state characteristic of TSE-associated
PrP-res [45]. This reaction is dependent upon time and
the concentrations of input PrPSc and PrP-sen [28]. This
cell-free conversion reaction has also proven to be highly
specific and reproduces strain-specific biochemical prop-
erties of different hamster-adapted TSE strains (see
Figure 1) [15]. Furthermore, the PrP sequence specifici-
ties of the conversion reaction correlate with interspecies
and intraspecies TSE transmissions in vivo [46–48]. The
products of cell-free conversion reactions have not yet
been shown to be infectious [49] (GJ Raymond and BC,
unpublished observations), although there are major
technical difficulties associated with such analyses given
the present state of the art. In any case, the strain and
species specificities of the cell-free conversion reactions
argue that this experimental system is relevant to TSE
biology and is a powerful tool for further analyses of the
direct interactions between PrP-res and PrP-sen under
defined conditions. In addition, the cell-free conversion
reactions have been used for practical purposes, such as
predicting possible risks of cross-species transmission of
TSE [48] and screening and analyzing the mechanism of
anti-TSE compounds [50–52]. 
Recently, more physiological conditions have been estab-
lished for the cell-free conversion reaction. For instance, an
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Figure 3
Antibody epitopes, glycans and potential
PrP-res-binding sites on the three-dimensional
NMR structure of a C-terminal fragment
(residues 90–231) of hamster PrP-sen [9].
(a) Backbone secondary structures and
(b) space-filling models are shown in front
and back views. The regular circles represent
residues in this fragment that are known to be
highly flexible [6,9]. In (a) the aspargine
residues to which glycans can be attached
are shown in yellow; in (b) the representative
glycans are also in yellow. The glycan
structures shown as space-filling models are
minimal generic N-linked glycan structures
(most N-linked glycans are larger than these).
In considering the effects of antibodies
binding to these epitopes, it is useful to bear
in mind that antibody molecules themselves
are much larger than PrP-sen itself and,
therefore, would be likely to block access to
more of the PrP-sen surface than just the
epitope residues themselves. Localized
surfaces that might be blocked by α219–232
(epitope shown in red) and not by the
antibodies to residues 90–104 (blue),
106–115 (black), 143–156 (green) or the
presence of glycans (yellow) are encircled
with dashed lines. These residues include the
extended chain of residues ~119–140, helical
residues ~206–223 and the loop of residues
~165 to 174 between the second β strand
and second α helix [55]. The residues
119 and 120 are included because of their
importance in the peptide inhibition of the
conversion reaction [50], their importance in
the initial binding reaction remains to be
determined, however. (The figure was
adapted from [55] with permission.) 
in situ conversion reaction has been shown to occur within
the context of intact brain tissue slices [53]. The elimina-
tion of denaturants has also allowed analyses of the impact
of biological factors in the conversion of PrP-sen to PrP-res
[54–56]. For instance, the chaperone proteins GroEL and
Hsp104 can stimulate the conversion reaction [54]. Kinetic
analyses under such conditions showed that the conversion
process can be separated into two stages: the binding of
PrP-sen to PrPSc followed by a slower conversion of the
bound PrP-sen to PrP-res [53–55]. Studies using anti-PrP
antibodies provided information about the PrP-sen domain
that is involved in the initial binding between PrP-sen and
PrPSc [55] (Figure 3). Among the anti-PrP antibodies
tested, only antibodies against the C terminus of PrP
(α219–232) inhibited the initial binding of PrP-sen to
PrPSc. However, removal of the α219–232 epitope from
PrP-sen did not affect its binding to PrP-res, suggesting
that it was not the epitope itself that was involved in
PrP-res binding but residues close to it in three-dimen-
sional space that are sterically hindered by antibody
binding. Several surfaces fit this description (Figure 3),
including the extended chain of residues ~119–140, helical
residues ~206–223 and the loop of residues ~165–174
between the second β strand and second α helix [55]. The
importance of residues in the 119–140 region has also been
suggested by the inhibition of the conversion reaction by
peptides fragments from this region [50,57].
Considering these data and the apparent importance of the
disulfide bond between residues 179 and 214 in the conver-
sion of PrP-sen to PrP-res [17,58], we speculate that 
disruption of the disulfide bond may increase the distance
between the third helix and the loop of residues ~165–174,
thereby decreasing the binding affinity of PrP-sen for PrPSc
or the ability of bound PrP-sen to convert to the protease-
resistant state. Thus, it seems likely that discontinuous
regions of the molecules are involved in the interactions.
Furthermore, amino acid substitutions in these regions
affected PrP-res formation in scrapie-infected cells [59].
Although the authors proposed an unidentified factor,
protein X, to explain the inhibition of PrP-res formation by
point mutations in these regions, it is also possible that the
mutations affect the direct binding and/or conversion of
PrPC to PrPSc. The ability of such mutants to inhibit PrPSc
formation in trans may be due to an ability to bind wild-
type PrP-res, and, without converting themselves, to block
the binding and conversion of wild-type PrPC [60].
As noted above, cell-free conversion systems have been
used to dissect the conversion process into the initial
binding and conversion steps to PrP-res by kinetic means
[54,55]. More recently, we have also segregated conver-
sion from the initial binding in cell-free studies using
heterologous mouse and hamster PrP isoforms. Consistent
with the difficulties of transmitting mouse scrapie agent to
hamsters or vice versa, full conversion of PrP-sen with the
heterologous PrPSc is inefficient [46]. However, we recently
found that the binding of PrP-sen to heterologous PrPSc
occurred efficiently even without conversion to PrP-res
(MH, S Priola and BC, unpublished results). This suggests
that the species specificity of PrP-res formation is deter-
mined by the conversion step rather than the initial binding
step. In addition, these studies imply that the binding and
conversion steps involve at least partially different mecha-
nisms. Indeed, as is also suggested by the PrPSc unfolding
studies described below [28,29], there may be two types of
PrP-sen-binding sites on PrP-res — one that is ‘conversion
competent’ (e.g., at the fibril ends in Figure 4) and another
that is not (e.g., along the sides of fibrils in Figure 4). The
initial binding of PrP-sen to PrP-res may take place in the
domain that is proximal in space to the C-terminal residues
219–232 in a manner that is less sequence-specific than the
proceeding events that occur at conversion-competent sites
and are required for the conversion of PrP-sen to the
PK-resistant state. Studies using mouse–hamster chimeric
PrP showed that the central part of the PrP-sen molecule,
including three amino acid substitutions at 138/139, 154/155
and 169/170, is important in the conversion of PrP-sen to
PrP-res [46,60–62]. Thus, it is possible that critical interac-
tions in the vicinity of these residues on PrP-sen and/or
PrPSc occur as part of the conversion step.
PrPSc unfolding/refolding studies
Clues to the folding of PrP-res have been obtained from
analyses of the effects of denaturants. Detailed studies of
hamster PrPSc unfolding and disaggregation concluded that
guanidine (Gdn) HCl and acid (< pH 2) treatments irre-
versibly disaggregate and denature PrPSc via a monomeric
molten globule intermediate [63,64]. The pathway was
described as having four sequential stages — aggregates,
dissociated folded monomers, partially unfolded interme-
diates, and unfolded monomers — with the formation of
the dissociated folded monomer occurring fully at a con-
centration of 1.5 M GdnHCl. The suggested involvement
of a molten globule intermediate is consistent with the
observation of stable folding intermediates of various
recombinant PrP molecules under certain conditions (see
below). However, other aspects of this proposed pathway
are at odds with more recent studies of the unfolding of
PrPSc [28,45,65]. For instance, at ≤ 3 M Gdn HCl concen-
trations there is a reduction of the average size of PrPSc
aggregates, as evidenced by reduced turbidity [63], but the
original protease-resistant PrPSc molecules remain polymer-
ized. A sizable subfraction of PrPSc-associated PrP mol-
ecules appear to be monomerized by this treatment, but
this subfraction appears to comprise PrP-sen molecules that
copurify with PrPSc aggregates and are easily stripped away
from the core PrP-res molecules and scrapie infectivity
[28,29,65]. Another inconsistency with the initial model is
that partial, reversible unfolding of residues ~90–115 in the
PK-resistant PrPSc polymers occurs prior to monomerization
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and full denaturation of the protease-resistant PrPSc-
derived molecules [28,65]. Our current working model for
the GdnHCl-induced unfolding of PrPSc (not pretreated
with PK) is shown in Figure 4. 
Oesch et al. [66] monitored changes in the PK resistance of
PrPSc induced by Gdn thiocyanate, urea and pH changes
and estimated free energies of PrPSc in the absence of
denaturants. On the basis of these studies they propose a
two-state model for PrPSc unfolding that involves a minor
conformational change of a single protein domain.
However, their assay monitored changes in the PK resis-
tance of only a single monoclonal antibody epitope on
PrPSc, which might have provided an oversimplified view
of changes occurring in the whole molecule.
Variable results have been obtained in trying to reverse
loss of infectivity due to denaturation. McKenzie et al. [67]
concluded that the addition of copper ions aids in the
refolding of PrPSc after partial unfolding in GdnHCl and
the apparent loss of TSE infectivity. However, others
have not been able to restore scrapie infectivity lost to
treatments with urea, chaotropic salts, and sodium dodecyl
sulfate (SDS) [40,68–70]. For instance, Riesner et al.
[68,70] showed that purified PK-treated PrP-res fibrils can
be disrupted with SDS to form 10 nm spherical particles
with high α-helical content and no PK resistance or infec-
tivity. Upon removal of the detergent or addition of 25%
acetonitrile, multimeric PK-resistant forms with a high
content of β sheet were generated that lacked infectivity.
Aggregated and PK-resistant forms of PrP have also been
generated after dimethyl sulfoxide (DMSO) treatment of
PrPSc, but have an amorphous ultrastructure and much
reduced infectivity [71]. Collectively, these and other
studies (e.g., [49]) indicate that PK resistance and insolu-
bility alone are not sufficient for PrP to be infectious.
Modeling PrP-res formation with synthetic PrP peptides
Early attempts to model experimentally fibril formation
and the conformational conversion of PrP-sen to PrP-res
were performed using short synthetic peptide fragments
of the PrP amino acid sequence [12,72–76]. These studies
revealed that, as is the case with numerous other small
peptides, certain PrP peptides with disordered or helical
structures in solution can polymerize into fibrils with a
high β-sheet content. This process occurs by a nucleated
polymerization mechanism [74]. When in vast stoichio-
metric excess, hamster PrP synthetic peptides comprising
residues 90–145 and 109–141 enhance the PK resistance
of PrP-sen [77]. The total protease resistance of PrP-sen
observed in these peptide mixtures, however, was not the
characteristic partial PK resistance exhibited by bona fide
PrP-res. Although these peptide studies revealed impor-
tant mechanistic possibilities, it remains to be determined
how well they approximate to the structural transitions of
whole PrP molecules.
Unfolding and refolding of recombinant PrP molecules
Longer portions of the PrP sequence have been expressed
in bacteria and used in PrP structure and folding studies.
The C-terminal residues (121–231) of mouse PrP act as an
‘autonomous folding unit’ which undergoes a cooperative
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Figure 4
Working model for the unfolding of PrPSc. At
a concentration of 1.5–3 M GdnHCl, several
events take place: a population of tightly
bound PrP-sen molecules are stripped off
oligomers/multimers of PrP-res;
superaggregates of fibrillar or protofibrillar
polymers are dissociated without
depolymerization of the core polymers; and a
portion of each monomer within the core
fibrils or protofibrils is reversibly unfolded,
leaving the remaining C-terminal domain
(residues ~121–228) folded and
PK-resistant. With higher GdnHCl
concentrations, the fibrils/protofibrils are
depolymerized and the PrP-res molecules are
irreversibly denatured. Concomitant with the
latter changes are the loss of associated
scrapie infectivity and PrP-res in vitro self-
propagating activity [29].
PrP-res (full-length)
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PrP-res (truncated)
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and reversible unfolding/refolding transition in the presence
of GdnHCl with a free energy of folding of –22 kJ/mol at
pH 7 [78]. Subsequent stopped-flow studies indicated that
the folding of this PrP fragment was possibly the fastest
protein folding reaction known at that time, with a deduced
half-life of ~170 µs at 4°C without detectable intermediates
at neutral pH [79]. At acidic pH, however, a high β-sheet
equilibrium folding intermediate of this fragment was
detected [38]. 
A similar scenario was observed in studies of a larger frag-
ment of recombinant human PrP (residues ~90–231) [36].
At near neutral pH, a cooperative two-state GdnHCl-
induced unfolding was observed. However, at more acidic
pH, a folding intermediate with a high content of β-sheet
and exposed hydrophobic surfaces was stabilized. A similar
fragment of hamster PrP has been shown to assume two
different α-helical states: one obtained directly from an
acid environment and another refolded at near neutral pH
[37]. Only the latter was soluble at physiological pH. The
high α-helical state required the formation of a disulfide
bond between the two cysteine residues in PrP. On the
other hand, insoluble, high-β-sheet forms were obtained
with or without the intramolecular disulfide bond. More
recently, a monomeric, high-β-sheet, PK-resistant and fib-
rillogenic form of human PrP residues 91–231 was
reversibly generated by reducing the disulfide bond and
dropping the pH to 4 [39]. As PrP-res formation may occur
in endosomes or lysosomes in scrapie-infected cells
[80–82], it is possible that acidification and redox changes
in those compartments could influence the PrPC → PrPSc
transformation. However, certain observations are inconsis-
tent with the idea that reduction of the disulfide bond is
critical for PrPSc formation: PrPSc contains intact disulfide
bonds [83]; the substitution of Cys178 with alanine pre-
vented PrP-res formation in scrapie-infected cells [17]; and
the reduction of the disulfide bond in PrPC inhibits its
PrPSc-induced conversion to PrP-res in vitro [58].
Do mutations destabilize PrPC and facilitate PrP-res
formation?
At present, 12 point mutations and several insertions are
found to be associated with inherited human TSE. The
concept that mutation-induced destabilization of protein
facilitates amyloid fibril formation is well established in
some amyloidoses. In some inherited human TSEs, only
PrP from the mutant allele deposits in PrP plaques
[16,84,85]. Therefore, it is of interest to know whether
PrP-sen encoded by mutant alleles is destabilized and
readily forms amyloidogenic conformers that are prone to
aggregation and PrP-res formation.
Mutant PrP molecules corresponding to those found in
certain inherited human TSEs can be inappropriately
compartmentalized within cells and display some bio-
chemical characteristics of PrP-res such as detergent
insolubility and relative resistance to PK digestion, albeit
much less PK resistance than that of PrP-res in brains of
TSE-infected animals [86–90]. Although no infectivity
has been demonstrated for PrP-res-like aggregates gener-
ated in tissue culture cells, these results suggest that at
least some mutant PrP molecules can have a predisposi-
tion to form PrP-res-like aggregates.
Some mutant PrPs have shown an aberrant metabolism in
tissue cultured cells and/or in the brain of patients [89,91].
This suggested that the expression and accumulation of
mutant PrP in inappropriate compartments may be the
primary cause of at least some inherited human TSEs.
Indeed, transgenic mice expressing PrP with particular
deletions or mutations, albeit not TSE-associated muta-
tions, develop neurological disorders that appear to be
caused by aberrant targeting of mutant PrP without appar-
ent accumulation of PrP-res [91,92].
Recent biophysical studies using recombinant PrP con-
taining TSE-specific point mutations directly addressed
the question of whether amino acid changes alter the
secondary structure and/or destabilize PrP molecules. In
CD spectroscopy experiments, recombinant human PrP
(residues 90–231) containing a Pro102 → Leu or
Glu200 → Lys mutation [93], and eight recombinant
mouse PrPs (residues 121–231) containing various point
mutations [94] showed an α-helical content essentially
identical to wild-type PrP and no increased β-sheet
content. These results suggest that these mutations do
not affect the secondary structure of PrP-sen. However,
others have reported that recombinant mouse PrP
(residues 23–231) containing a Pro102 → Leu mutation
displayed decreased α-helical content [95]. The differ-
ent results may be due to the difference in length and/or
species of the PrP fragment used. In addition, some, but
not all, of the recombinant mouse PrP containing muta-
tions (Asp178 → Asn, Thr183 → Ala, Phe198 → Ser or
Gln217 → Arg) showed lower thermodynamic stability
than the wild-type PrP [94]. Measured thermodynamic
stabilities appeared to match the stabilities predicted on
the basis of the NMR structure of recombinant mouse
PrP [96]. In assessing the biological ramifications of
analyses of these recombinant forms of PrP-sen, it
should also be considered whether the addition of
copper ions, the GPI anchors or carbohydrate chains
would modulate the folding and stability of the various
PrP molecules. Nonetheless, it appears that although the
mutation-induced destabilization concept might explain
the mechanism of PrP-res formation for particular muta-
tions (such as Asp178 → Asn), it is not a general mecha-
nism underlying stochastic PrP-res formation in
inherited human TSE [93,94]. Some mutations might
instead increase stochastic conversion by stabilizing the
transition state and thereby lowering the activation
energy barrier. 
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Future challenges
Although great progress has been made in understanding
the structures of PrP-sen molecules, our understanding of
PrP-res structure remains primitive and low-resolution. It
seems likely that new methods of high-resolution protein
conformational analysis will be required to solve the struc-
ture of PrP-res and other amyloid-like protein aggregates.
Another fundamental unresolved question that has
haunted the TSE field for decades is the precise nature of
the infectious TSE agent or prion. Although considerable
circumstantial evidence suggests that an abnormal form of
PrP alone may be the culprit, a measure of skepticism is
warranted until a pure, noninfectious form of PrP is con-
verted to an agent that causes TSE disease when injected
into animals.
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